The COMPASs Study: Community Preferences for Prostate cAncer Screening. Protocol for a quantitative preference study by Howard, Kirsten et al.
The COMPASs Study: Community
Preferences for Prostate cAncer
Screening. Protocol for a quantitative
preference study
Kirsten Howard,1 Glenn P Salkeld,1 Graham J Mann,2 Manish I Patel,3
Michelle Cunich,1 Michael P Pignone4
ABSTRACT
Background: Prostate cancer screening using
prostate-specific antigen (PSA) testing remains
controversial. Trade-offs between the potential benefits
and downsides of screening must be weighed by men
deciding whether to participate in prostate cancer
screening; little is known about benefit:harm trade-offs
men are willing to accept.
Methods/Design: The Community Preferences for
Prostate Cancer Screening (COMPASs) Study
examines Australian men’s preferences for prostate
cancer screening using PSA testing. The aims are to
(1) determine which factors influence men’s decision
to participate in prostate cancer screening or not and
(2) determine the extent of trade-offs between benefits
and harms that men are willing to accept in making
these decisions. Quantitative methods will be used to
assess men’s preferences for PSA screening. Using
data on the quantitative outcomes of PSA testing from
the published literature, a discrete choice study will be
designed to quantitatively assess men’s preferences. A
web-based survey will be conducted in approximately
1000 community respondents aged 40e69 years,
stratified by family history of prostate cancer, to
assess men’s preferences for PSA testing. A mixed
logit model will be used; model results will be
expressed as parameter estimates (b) and the odds of
choosing screening over no screening. Trade-offs
between attributes will also be calculated.
Ethics and Dissemination: The COMPASs study has
been approved by the University of Sydney, Human
Research Ethics committee (Protocol number 13186).
The results will be published in internal reports, in
peer-reviewed scientific journals as well as via
conference presentations.
BACKGROUND
Screening for prostate cancer using prostate-
specific antigen (PSA) testing remains
controversial. Recently published evidence
suggests that prostate cancer screening using
PSA testing may offer some benefits in
terms of reducing prostate cancer-specific
mortality; no trials have demonstrated
a reduction in overall mortality associated
with screening.1 2 However, these same trials
also report evidence of substantial harms:
men who participate in screening have
a significantly higher likelihood of being
diagnosed as having prostate cancer than
those not screened, including the diagnosis
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- To assess men’s preferences for prostate cancer
screening and determine the relative importance
of various factors that influence men’s decision
to participate in prostate cancer screening or not.
- To determine the extent of trade-offs between
benefits and harms that men are willing to accept
in making decisions about participation in
screening.
Key messages
- Prostate cancer screening may offer some
benefit in terms of a reduction in prostate
cancer-specific mortality. However, there is also
evidence of substantial harms: screened men
have a higher likelihood of being diagnosed as
having prostate cancer, including the diagnosis
of cancers that would not have become clinically
apparent within the man’s lifetime, meaning
more men experiencing the attendant harms of
diagnosis and treatment such as unnecessary
biopsies from false-positive prostate-specific
antigen tests or impotence and/or incontinence
from treatments.
- Trade-offs between the potential benefits and
downsides of screening must be weighed by men
deciding whether to participate in prostate cancer
screening; little is known about benefit:harm
trade-offs men are willing to make.
- This study will use best practice quantitative
methods for preference elicitation (discrete
choice experiments) to assess men’s preferences
for prostate-specific antigen screening and the
trade-offs they are willing to make decision
whether to participate in screening.
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of cancers that would not have become clinically
apparent within the man’s lifetime, meaning that more
men experiencing the attendant harms of diagnosis and
treatment such as unnecessary biopsies from false-posi-
tive PSA tests or impotence and/or incontinence from
treatments.1e3 In deciding whether to undergo prostate
cancer screening, men therefore need to weigh up these
potential benefits with the potential risks, harms and
costs associated with screening.
Adding to the complexity and uncertainty in this
decision-making environment are the somewhat
conflicting recommendations regarding the value of
prostate cancer screening: the American Urological
Association recommends PSA screening be offered to all
men aged 40 years or older.4 Other US groups recom-
mend discussion of the potential benefits and harms of
PSA screening in the context of a clinical consultation,
with an emphasis on informed decision making and
consideration of patient preferences (the American
Cancer Society,5 the American College of Physicians6).
In Australia, the Cancer Council of Australia’s position
on prostate cancer indicates “there is no national
screening program in place, with current evidence
showing that the PSA test is not suitable for population
screening as the harms outweigh the benefits. Whether
or not to be tested for prostate cancer is a matter of
individual choice.”.7 The most recent draft guidelines
from the US Preventive Services Task Force (USPSTF)
go one step further and assign a ‘D’ rating to PSA
screening “recommends against prostate-specific
antigen (PSA)-based screening for prostate cancer.
[for] men in the US population that do not have
symptoms that are highly suspicious for prostate cancer,
regardless of age, race, or family history.”8 This revised
recommendation will replace the 2008 recommenda-
tion,9 which had previously concluded that in men
younger than 75 years, there was insufficient evidence to
make a recommendation (‘I’ rating).
CONSUMER PREFERENCES FOR SCREENING
Over recent years, there has been an increasing recog-
nition of the role and importance of preferences and
values in individual clinical decisions and in shaping
public health policy. Preference sensitive care refers to
care where there are significant potential trade-offs
among possible positive and negative outcomes;
decisions regarding these interventions should neces-
sarily reflect an individual’s personal values and prefer-
ences and should be made only after individuals have
considered sufficient information to make an informed
choice.10 It has recently been suggested that prostate
cancer screening should be viewed as preference
sensitive care.11
There is an extensive body of literature quantifying
preferences and trade-offs for bowel cancer screen-
ing12e16; however, despite the clear balance between
harms and benefits in the context of PSA screening for
prostate cancer, there has, to date, been little explora-
tion of these issues. With possible benefits to screening
in terms of prostate cancer-specific mortality reduction,
there is also evidence of significant and multiple
potential downsides. A decision about whether to
participate in prostate cancer screening therefore
requires consideration of the balance between these
benefits and downsides. Where that balance sits for an
individual man is highly personal and driven by his own
preferences about the extent of trade-offs between
benefits and harms that he is willing to accept. For this
reason, the preferences of the individual should be
paramount.
The aims of the Community Preferences for Prostate
Cancer Screening (COMPASs) Study are therefore to
< determine the relative importance of various factors
that influence men’s decision to participate in
prostate cancer screening or not and
< determine the extent of trade-offs between benefits
and harms that men are willing to accept in making
decisions about participation in screening.
By providing a better understanding of how men value
particular aspects of prostate cancer screening and the
trade-offs between benefits and harms of PSA screening
that they are willing to accept, the COMPASs Study will
provide vital information (1) for clinicians and
consumers to facilitate an informed discussion of the
potential benefits and downsides of PSA testing, (2) to
inform health policy regarding the development of any
possible future public screening programme such that
any programme can be closely aligned to community
attitudes and preferences and (3) highlight future
research directions such that research and subsequent
policy development can be focused in areas of most
importance to consumers.
METHODS/DESIGN
Overview of approach and methods
The COMPASs Study will use quantitative discrete choice
methods to assess Australian men’s preferences for
prostate cancer screening.
Discrete choice experiments
Discrete choice experiments (DCEs) involve surveys in
which respondents are asked to choose between
hypothetical alternatives defined by a set of differing
attributes. This method is becoming more widely used
ARTICLE SUMMARY
Strengths and limitations of this study
- The strengths of the study are that it is the first study to use
discrete choice methods to examine men’s preferences for
prostate cancer screening, and the benefit:harm trade-offs men
may be willing to make; it will consider the influence of age and
family history on preferences in a large cohort of men, broadly
representative of the Australian population aged 40 to 69 years.
- The limitation is that it is conducted in one country, Australia,
and thus its generalisability may be limited by the prevailing
screening environment.
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in health as a means of quantifying patient and
consumer preferences for healthcare policies and
programmes.17e20 The method is based on the idea that
goods and services, including healthcare services, can be
described in terms of a number of separate attributes or
factors. The levels of attributes are varied systematically
in a series of questions and respondents choose the
option that they prefer for each question. People are
assumed to choose the option that is most preferred or
has the highest ‘value’. From these choices, a mathe-
matical function is estimated that describes numerically
the value that respondents attach to different choice
options. Other data collected in the survey, including
attitudinal questions and socio-demographic informa-
tion, may also enter the value functions as explanatory
variables. Ultimately, DCE studies can determine which
attributes are driving patient preferences, the trade-offs
people make between attributes and how changes in
attributes can lead to changes in preferences and likely
service uptake.
Figure 1 illustrates an example from an Australian
survey of consumer preferences for colorectal cancer
screening tests.16 The example involves two unlabelled
alternative tests (figure 1) described using five different
attributes (how many cancers the test will find, how
many large polyps the test will find, the number of
people correctly reassured that they do NOT have
cancer, cost, dietary and medication restrictions, stool
sample collection), each set at specific levels. By
presenting respondents with a series of choices where
the levels of the attributes are varied, researchers are
able to quantify how these attributes influence choice. In
this example, the analysis indicates consumer prefer-
ences for immunochemical faecal occult blood testing as
a screening test for colorectal cancer.
Given a sufficient number of choices to allow variation
across all attributes, this approach enables estimates of
the marginal effect of each attribute on choice and the
marginal rate of substitution or trade-offs between attri-
butes. In principle, this can be done by offering
respondents choices using every combination of attri-
butes, a ‘full factorial’ design. In practice, such a design
is rarely feasible; efficient designs are therefore para-
mount, particularly when considering multiple choice
options and interactions between attributes and socio-
demographic characteristics on choice.
The following section details the specific methods that
will be applied in the COMPASs Study; we will follow the
ISPOR Guidelines for Good Research Practices for
conjoint analysis in health.20
STUDY METHODS
Stage 1: deciding attributes and levels
A systematic review of the literature will be conducted to
ascertain attributes for inclusion. These will include PSA
test performance characteristics, such as potential
mortality benefits from screening, number of diagnoses
of prostate cancer as well as harms such as the number of
men experiencing false-positive PSA results and subse-
quent unnecessary biopsies, potential harms associated
with downstream treatment of prostate cancer, such as
impotence and urinary or faecal incontinence21 and out
of pocket costs. Our existing published model3 will be
used to estimate these outcomes in men who screen and
who do not screen, over a 10-year time frame. Model
outputs, and therefore attribute levels, will be stratified
by age and risk based upon family history.
Stage 2: design of discrete choice questionnaires
Once the attributes have been decided based on stage 1,
a design for the discrete choice studies will be created.
Statistically efficient designs will be used. This approach
to design links statistical efficiency to the likely econo-
metric model that is to be estimated from choice data
using the design.22 23 This approach relaxes the
orthogonality constraint and attempts to minimise the
Figure 1 Example of a discrete
choice question.
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expected asymptotic varianceecovariance (AVC) matrix
of the design. Efficient choice designs therefore attempt
to maximise the likely asymptotic t ratios obtained from
choice data collected. As such, they attempt to minimise
the correlation in the data for estimation purposes and
collect data such that parameter estimates have as small
as possible SEs. These designs make use of the fact that
the AVC matrix (the roots of the diagonal of this matrix
are the asymptotic SEs) of the parameters can be derived
if the parameters are known. Since the objective of the
DCE is to estimate these parameters, they are unknown
at the time of design. However, if some prior information
about these parameters is available (eg, parameter esti-
mates available in the literature from similar studies or
parameter estimates from pilot studies), then this AVC
matrix can be determined, assuming that the priors are
correct.
An initial efficient choice design will be created, based
on the likely a priori sign of parameters. This initial
design will be piloted in a sample of 100 respondents
and preliminary models estimated. Parameter estimates
from the models will be used to generate the final
efficient designs for the main discrete choice study.
In addition to the discrete choice questions, informa-
tion on socio-demographic characteristics of respon-
dents will also be collected for each survey.
Stage 3: DCE survey
Respondents
Men aged 40e69 years of low, moderate and high risk of
prostate cancer, based upon family history of prostate
cancer, will be recruited to complete the DCE survey.
Low-risk men are those with no first-degree relatives
(FDR) affected by prostate cancer. Men with one
affected FDR are considered at moderate risk and men
with either two or more affected FDR or one FDR diag-
nosed at a young age (<60 years) are considered at high
risk. Based on their age and family history of prostate
cancer, they will be allocated to a version of the survey
with attribute levels relevant to their age and risk. No
additional exclusion criteria will be applied.
The DCE will be conducted using a web-based
survey. Respondents will be recruited through a market
research company with an existing online panel of
respondents willing to complete online surveys and
experience in administering online choice-based
surveys. Recruitment will continue until the proposed
sample size is reached. Upon consent, the potential
respondent will be connected directly to the online site
to complete the discrete choice survey. Respondents will
be asked to choose between three labelled alternatives,
two screening options and a no screening option
(opt-out).
Sample size
The current theory of sampling for these experiments
does not directly address the issue of minimum sample
size requirements in terms of the reliability of the
parameter estimates produced in the design of stated
choice experiments.24 25 Rather, sampling theory as
applied to choice modelling is designed to minimise the
error in the choice proportions of the alternatives under
study. This means that the final sample size required is
based upon the characteristics of the design itself such as
the number of attributes included, the attribute level
range, the number of choice scenarios presented, the
number of alternatives in each choice set and the size
and direction of prior parameters obtained from the
pilot study. Taking into account the Australian popula-
tion distribution of men aged 40e69 years with different
levels of family history of prostate cancer (low, no
FDR w94% of the population aged 40e69 years;
moderate, one FDR w5% to 6%; high, two FDR or one
FDR diagnosed <60 years w0.5%) and to ensure
sufficient numbers in risk subgroup for robust param-
eter estimates and that we are able to explore interac-
tions between attributes and between attributes and
socio-demographic factors and present subgroup anal-
yses, we anticipate a sample size of approximately 1000
respondents (550 (low), 350 (moderate) and 100
(high)).
Stage 4: analysis
A mixed multinomial logit (MMNL) (also known as
random parameters logit) model using a panel size
specification will be used. A panel specification of the
model allows for non-independence of observations
provided by the same respondent; that is, it can account
for correlations among the multiple choices made by the
same individual. MMNL models relax certain statistical
assumptions of more commonly used multinomial logit
models and often lead to models that better explain
choice behaviour.24 In multinomial logit choice models,
commonly used in health economics, parameters asso-
ciated with each attribute are treated as fixed. These
fixed values are the average (or point estimates) associ-
ated with a population-level distribution; other infor-
mation in the distribution is not considered. An MMNL
allows consideration of the full distribution of a param-
eter estimate, and the fixed parameter becomes
a random parameter. ‘Random parameter’ simply
implies that each individual has an associated parameter
estimate on that specified distribution. While the exact
location of each individual’s preferences on the distri-
bution may not be known, estimates of ‘individual-
specific preferences’ can be accommodated by deriving
the individual’s conditional distribution, baseddwithin
sampledon their choices (ie, prior knowledge).26
Interactions between attributes in the discrete choice
surveys and between attributes and population charac-
teristics (eg, age, family history of prostate cancer, prior
PSA testing, prior prostate biopsy, marital status, educa-
tion, income) will be explored in the mixed logit analysis
for both studies.
Model results will expressed as parameter estimates
(b), the odds of choosing screening over no screening
(and 95% CIs of the ORs) and p values. Acceptable
trade-offs between attributes will also be calculated.
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ETHICAL APPROVAL
The COMPASs Study has been approved by the Univer-
sity of Sydney, Human Research Ethics Committee
(protocol number 13186).
Confidentiality and anonymity of the data will be
strictly maintained; only study staff will have access to de-
identified respondent data. As respondents are being
recruited by an external organisation, no individual
identifying information will be ever provided to the
study investigators; all respondents will be assigned
a unique study ID. In addition, participants will not be
identifiable in any publications. It will be made clear to
all participants that they have the right to withdraw from
the research at any point in time. No data monitoring
committee will be required, and no interim analyses will
be conducted.
As the DCE survey will be conducted as an online
survey, written consent is not possible. As such, partici-
pant information for the online survey includes the
following statement “Being in this study is completely
voluntarydyou are not under any obligation to consent
anddif you do consentdyou can withdraw at any time
without affecting your relationship with The University of
Sydney. By completing the survey you have consented to
be part of the study. You may stop completing the online
survey at any point if you do not wish to continue, and we
will not use your answers”. As the survey is administered
by an external organisation and is completely online, the
study team will not have access to any information that
could be used to identify respondents. Following study
completion, only study investigators will have access to
the de-identified respondent data.
DISSEMINATION
The results will be published in internal reports, in peer-
reviewed scientific journals as well as via conference
presentations.
DISCUSSION
The COMPASs Study is a comprehensive analysis of
men’s preferences for prostate cancer screening. Using
best practice quantitative methods, COMPASs will
provide an understanding of the preferences of Austra-
lian men on prostate cancer screening using PSA testing.
Specifically, the aims of the COMPASs study are to (1)
determine the relative importance of various factors that
influence men’s decision to choose prostate cancer
screening or not and (2) determine the extent of trade-
offs between benefits and harms that men are willing to
accept in making decisions about participation in
screening.
The analysis will provide:
< Estimates of the marginal effect (importance) of each
attribute on the decision to screen or not, for
example, if a cost attribute is presented, the analysis
will provide an estimate of relative importance of out
of pocket cost on a man’s decision to undergo
prostate cancer screening.
< Estimates of marginal rates of substitution between
attributes based on the ratio of parameter estimates,
giving an indication of the extent to which respon-
dents are prepared to trade-off one attribute for
another. For example, if the number of deaths due to
prostate cancer and the number of men experiencing
incontinence are offered as attributes in the survey,
the marginal rate of substitution between these
reflects the increase in the number of men experi-
encing incontinence that men are willing to accept as
a trade-off to prevent one extra prostate cancer death.
< An indication of the predicted uptake associated with
different parameter levels within the estimated utility
functions. This allows forecasting of, for instance, the
likely level of uptake of screening given particular test
characteristics, policy criteria and socio-demographic
characteristics.
By providing a better understanding of how men value
particular aspects of prostate cancer screening and the
trade-offs between benefits and harms of PSA screening
that they are willing to accept, the COMPASs Study will
provide vital information (1) for clinicians and
consumers to facilitate an informed discussion of the
potential benefits and downsides of PSA testing, (2) to
inform health policy regarding the development of any
possible future public screening programme such that
any programme can be closely aligned to community
attitudes and preferences and (3) highlight future
research directions such that research and subsequent
policy development can be focused in areas of most
importance to consumers.
Funding The COMPASs Study is funded under the National Health and Medical
Research Council of Australia program grant 633003 (The Screening and Test
Evaluation Program). The funders have no role in study design; collection,
management, analysis and interpretation of data; nor in writing of any reports
or the decision to submit the reports for publication.
Competing interests None.
Ethics approval The COMPASs study has been approved by the University of
Sydney, Human Research Ethics Committee (protocol number 13186). The
results will be published in internal reports, in peer-reviewed scientific journals
as well as via conference presentations.
Contributors KH conceived the original concept of this study. All authors
contributed to discussion and revisions to the study design and approved the
final study design. KH drafted the manuscript; all other authors were involved
in overall revision of the manuscript. All authors are involved in the
implementation of the project and have read and approved the final
manuscript.
Provenance and peer review Not commissioned; internally peer reviewed.
REFERENCES
1. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-
cancer mortality in a randomized European study. N Engl J Med
2009;360:1320e8.
2. Andriole G, Grubb RL, Buys SS, et al. Mortality results from
a randomized prostate-cancer screening trial. N Engl J Med
2009;360:1310e19.
3. Howard K, Barratt A, Mann GJ, et al. A model of prostate-specific
antigen screening outcomes for low- to high-risk men: information to
support informed choices. Arch Intern Med 2009;169:1603e10.




Howard K, Salkeld GP, Mann GJ, et al. BMJ Open 2012;2:e000587. doi:10.1136/bmjopen-2011-000587 5
The COMPASs Study
5. American Cancer Society. Can Prostate Cancer be found early?
2010. http://www.cancer.org/docroot/CRI/content/CRI_2_4_3X_Can_
prostate_cancer_be_found_early_36.asp?sitearea (accessedOct 2011).
6. American College of Physicians. Screening for prostate cancer. Ann
Intern Med 1997;126:484.
7. Cancer Council Australia. Position Statement - Prostate Cancer.
2010. http://www.cancer.org.au/policy/positionstatements/
prostatecancer.htm (accessed 18 Oct 2011).
8. US Preventive Services. Screening for prostate cancer: U.S.
Preventive services Task Force recommendation statement
(DRAFT). 2011. http://www.uspreventiveservicestaskforce.org/
draftrec3.htm (accessed 18 Oct 2011).
9. US Preventive Services. Screening for Prostate Cancer. 2008. http://
www.ahrq.gov/clinic/uspstf/uspsprca.htm (accessed 2 Jun 2008).
10. Dartmouth Atlas Projeect. Preference sensitive care. A Dartmouth
Atlas Project Topic Brief. 2011. http://www.dartmouthatlas.org/
downloads/reports/preference_sensitive.pdf
11. O’Donnell J. Help me in my confusion: should we think more about
mammography and colonoscopy as “preference sensitive care”?
J Cancer Educ 2010;25:471e2.
12. Gyrd-Hansen D, Sogaard J. Analysing public preferences for cancer
screening programs. Health Econ 2001;10:617e34.
13. Marshall DA, Johnson FR, Phillips KA, et al. Measuring patient
preferences for colorectal cancer screening using a choice-format
survey. Value Health 2007;10:415e30.
14. Marshall DA, McGregor E, Currie G. Measuring preferences for
colorectal cancer (CRC) screening e What are the implications for
moving forward? The Patient - Patient Centred Outcomes Research
2010;3:79e89.
15. Salkeld G, Solomon M, Short L, et al. Evidence-based consumer
choice: a case study in colorectal cancer screening. Aust N Z J Public
Health 2003;27:449e55.
16. Howard K, Salkeld G. Does attribute Framing in discrete choice
experiments influence Willingness to Pay? Results from a discrete
choice experiment in screening for colorectal cancer. Value Health
2009;121:354e3.
17. Lancsar E, Louviere J. Conducting discrete choice experiments to
inform healthcare decision making: a user’s guide.
Pharmacoeconomics 2008;26:661e77.
18. Bridges JF, Kinter E, Kidane L, et al. Things are looking up
since we started listening to patients: recent trends in the
application of conjoint analysis in health 1970-2007. The Patient
2008;1:273e82.
19. Marshall DA, Bridges JF, Hauber AB, et al. Conjoint Analysis
Applications in Health - How are studies being designed and
reported? An update on current practice in the published literature
between 2005 and 2008. The Patient 2010;3:249e56.
20. Bridges JF, Hauber AB, Marshall DA, et al. Conjoint analysis
Applications in health-a Checklist: a report of the ISPOR good
research practices for conjoint analysis Task Force. Value Health
2011;14:5.
21. Smith DP, King MT, Egger S, et al. Quality of life three years after
diagnosis of localised prostate cancer: population based cohort study.
BMJ 2009;339:b4817.
22. Huber J, Zwerina K. The importance of utility balance in efficient
choice design. J Market Res 1996;XXXIII:307e17.
23. Sandor Z, Wedel M. Profile construction in experimental designs for
mixed logit models. Marketing Science 2002;21:455e75.
24. Hensher DA, Rose JM, Greene WH. Applied choice analysis. A
Primer. 1st edn. Cambridge: Cambridge University Press, 2005.
25. Louviere J, Hensher DA, Swait JD, et al. Stated Choice Methods -
Analysis. Cambridge University Press, 2000.
26. Hensher DA, Greene WH. The mixed logit model: the state of
practice. Transportation 2003;30:133e76.
6 Howard K, Salkeld GP, Mann GJ, et al. BMJ Open 2012;2:e000587. doi:10.1136/bmjopen-2011-000587
The COMPASs Study
